• 中国中文核心期刊
  • 中国科学引文数据库核心期刊
  • 中国科技核心期刊
  • 中国高校百佳科技期刊
高级检索

靶向MLL1-WDR5蛋白-蛋白相互作用抑制剂的研究进展

陈鑫, 杨倩, 尤启冬, 郭小可

陈鑫, 杨倩, 尤启冬, 郭小可. 靶向MLL1-WDR5蛋白-蛋白相互作用抑制剂的研究进展[J]. 中国药科大学学报, 2022, 53(2): 125-136. DOI: 10.11665/j.issn.1000-5048.20220201
引用本文: 陈鑫, 杨倩, 尤启冬, 郭小可. 靶向MLL1-WDR5蛋白-蛋白相互作用抑制剂的研究进展[J]. 中国药科大学学报, 2022, 53(2): 125-136. DOI: 10.11665/j.issn.1000-5048.20220201
CHEN Xin, YANG Qian, YOU Qidong, GUO Xiaoke. Advances of inhibitors targeting MLL1-WDR5 protein-protein interaction[J]. Journal of China Pharmaceutical University, 2022, 53(2): 125-136. DOI: 10.11665/j.issn.1000-5048.20220201
Citation: CHEN Xin, YANG Qian, YOU Qidong, GUO Xiaoke. Advances of inhibitors targeting MLL1-WDR5 protein-protein interaction[J]. Journal of China Pharmaceutical University, 2022, 53(2): 125-136. DOI: 10.11665/j.issn.1000-5048.20220201

靶向MLL1-WDR5蛋白-蛋白相互作用抑制剂的研究进展

基金项目: 国家自然科学基金资助项目(No.82173673,No.81872799);江苏省自然科学基金资助项目(No.BK20191321)

Advances of inhibitors targeting MLL1-WDR5 protein-protein interaction

Funds: This study was supported by the National Natural Science Foundation of China (No.82173673, 82173673); and the Natural Science Foundation of Jiangsu Province (No.BK20191321)
  • 摘要: Mixed lineage leukemia 1(MLL1)是组蛋白甲基转移酶SET家族的成员之一。MLL1与WDR5、RbBP5、Ash2L和DPY-30组成MLL1甲基转移酶复合物调控组蛋白H3的第4位赖氨酸的甲基化水平,对造血系统的发育和血细胞的更新至关重要。部分白血病患者体内存在因MLL1基因易位而产生的致癌蛋白——MLL1融合蛋白,MLL1融合蛋白在发挥其致癌作用时需要功能完整的MLL1酶复合物,故靶向MLL1-WDR5的蛋白-蛋白相互作用成为治疗MLL1融合型白血病的潜在策略。本文对MLL1-WDR5蛋白-蛋白相互作用的生物学机制、结构信息以及抑制剂进行了系统的总结,并结合已报道数据对该领域进行了展望,以期为后续研究提供参考。
    Abstract: Mixed lineage leukemia 1(MLL1) is a member of the "SET" histone methyltransferases family.MLL1 methyltransferase complex, consisting of MLL1, WDR5, RbBP5, Ash2L and DPY-30, regulates methylation level of histone H3 lysine 4 and is essential for the development of human hematopoietic system and self-renewal of blood cells.As an oncogenic protein produced by the translocation of MLL1 gene, the MLL1 fusion protein has been found in some patients with leukemia.Complete MLL1 enzyme complex is required to perform histone demethylation effect, therefore, targeting the protein-protein interaction of MLL1-WDR5 has become a potential strategy for the treatment of leukemia induced by MLL1 fusion protein.This review systematically summarizes the biological mechanism, structural information and inhibitors of MLL1-WDR5 protein-protein interaction, with a perspective based on previously reported data, aiming to provide some reference for further investigation.
  • [1] . Cell Metab,2019,29(5):1028-1044.
    [2] Cromby J,Chung E,Papadopoulos D,et al. Reviewing the epigenetics of schizophrenia[J]. J Ment Heal,2019,28(1):71-79.
    [3] Duruisseaux M,Esteller M. Lung cancer epigenetics:from knowledge to applications[J]. Semin Cancer Biol,2018,51:116-128.
    [4] Eckschlager T,Plch J,Stiborova M,et al. Histone deacetylase inhibitors as anticancer drugs[J]. Int J Mol Sci,2017,18(7):1414.
    [5] Jones PA,Issa JPJ,Baylin S. Targeting the cancer epigenome for therapy[J]. Nat Rev Genet,2016,17(10):630-641.
    [6] Jones PA,Baylin SB. The epigenomics of cancer[J]. Cell,2007,128(4):683-692.
    [7] Berger SL,Kouzarides T,Shiekhattar R,et al. An operational definition of epigenetics[J]. Genes Dev,2009,23(7):781-783.
    [8] Sheikhpour M,Maleki M,Ebrahimi Vargoorani M,et al. A review of epigenetic changes in asthma:methylation and acetylation[J]. Clin Epigenetics,2021,13(1):65.
    [9] Hyun K,Jeon J,Park K,et al. Writing,erasing and reading histone lysine methylations[J]. Exp Mol Med,2017,49(4):e324.
    [10] Kaniskan HU,Martini ML,Jin J. Inhibitors of protein methyltransferases and demethylases[J]. Chem Rev,2018,118(3):989-1068.
    [11] Ruthenburg AJ,Allis CD,Wysocka J. Methylation of lysine 4 on histone H3:intricacy of writing and reading a single epigenetic mark[J]. Mol Cell,2007,25(1):15-30.
    [12] Guenther MG,Jenner RG,Chevalier B,et al. Global and hox-specific roles for the MLL1 methyltransferase[J]. Proc Natl Acad Sci U S A,2005,102(24):8603-8608.
    [13] Dou Y,Milne TA,Tackett AJ,et al. Physical association and coordinate function of the H3K4 methyltransferase MLL1 and the H4K16 acetyltransferase MOF[J]. Cell,2005,121(6):873-885.
    [14] Daigle SR,Olhava EJ,Therkelsen CA,et al. Potent inhibition of dot1l as treatment of MLL-fusion leukemia[J]. Blood,2013,122(6):1017-1025.
    [15] Grembecka J,He S,Shi A,et al. Menin-MLL1 inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia[J]. Nat Chem Biol,2012,8(3):277-284.
    [16] Hess JL. MLL:a histone methyltransferase disrupted in leukemia[J]. Trends Mol Med,2004,10(10):500-507.
    [17] Glaser S,Schaft J,Lubitz S,et al. Multiple epigenetic maintenance factors implicated by the loss of MLL2 in mouse development[J]. Development,2006,133(8):1423-1432.
    [18] Butler LH,Slany R,Cui X,et al. The HRX proto-oncogene product is widely expressed in human tissues and localizes to nuclear structures[J]. Blood,1997,89(9):3361-3370.
    [19] Tkachuk DC,Kohler S,Cleary ML. Involvement of a homolog of drosophila trithorax by 11q23 chromosomal translocations in acute leukemias[J]. Cell,1992,71(4):691-700.
    [20] Cosgrove MS,Patel A. Mixed lineage leukemia:a structure-function perspective of the MLL1 protein[J]. FEBS J,2010,277(8):1832-1842.
    [21] Gu Y,Nakamura T,Alder H,et al. The T(4;11) chromosome translocation of human acute leukemias fuses the ALL-1 gene,related to drosophila trithorax,to the AF-4 gene[J]. Cell,1992,71(4):701-708.
    [22] Yokoyama A,Kitabayashi I,Ayton PM,et al. Leukemia proto-oncoprotein MLL is proteolytically processed into 2 fragments with opposite transcriptional properties[J]. Blood,2002,100(10):3710-3718.
    [23] Argiropoulos B,Humphries RK. Hox genes in hematopoiesis and leukemogenesis[J]. Oncogene,2007,26(47):6766-6676.
    [24] Dou Y,Hess JL. Mechanisms of transcriptional regulation by MLL and its disruption in acute leukemia[J]. Int J Hematol,2008,87(1):10-18.
    [25] Milne TA,Kim J,Wang GG,et al. Multiple interactions recruit MLL1 and MLL1 fusion proteins to the hoxa9 locus in leukemogenesis[J]. Mol Cell,2010,38(6):853-863.
    [26] Chang PY,Hom RA,Musselman CA,et al. Binding of the MLL1 PHD3 finger to histone H3K4me3 is required for MLL-dependent gene transcription[J]. J Mol Biol,2010,400(2):137-144.
    [27] Mcmahon KA,Hiew SY,Hadjur S,et al. MLL has a critical role in fetal and adult hematopoietic stem cell self-renewal[J]. Cell Stem Cell,2007,1(3):338-345.
    [28] Ansari KI,Kasiri S,Mandal SS. Histone methylase MLL1 has critical roles in tumor growth and angiogenesis and its knockdown suppresses tumor growth in vivo[J]. Oncogene,2013,32(28):3359-3370.
    [29] Scharf S,Zech J,Bursen A,et al. Transcription linked to recombination:a gene-internal promoter coincides with the recombination hot spot Ⅱ of the human MLL gene[J]. Oncogene,2007,26(10):1361-1371.
    [30] Yu BD,Hanson RD,Hess JL,et al. MLL,a mammalian trithorax-group gene,functions as a transcriptional maintenance factor in morphogenesis[J]. Proc Natl Acad Sci U S A,1998,95(18):10632-10636.
    [31] Winters AC,Bernt KM. MLL-rearranged leukemias-an update on science and clinical approaches[J]. Front Pediatr,2017,5:4.
    [32] Ayton PM,Cleary ML. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins[J]. Oncogene,2001,20(40):5695-5707.
    [33] Meyer C,Kowarz E,Hofmann J,et al. New insights to the MLL recombinome of acute leukemias[J]. Leukemia,2009,23(8):1490-1499.
    [34] Luo Z,Lin C,Shilatifard A. The super elongation complex(SEC) family in transcriptional control[J]. Nat Rev Mol Cell Biol,2012,13(9):543-547.
    [35] Nguyen AT,Zhang Y. The diverse functions of Dot1 and H3K79 methylation[J]. Genes Dev,2011,25(13):1345-1358.
    [36] Muntean AG,Hess JL. The pathogenesis of mixed-lineage leukemia[J]. Annu Rev Pathol,2012,7:283-301.
    [37] Milne TA,Martin ME,Brock HW,et al. Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus,promoting transcription and multiple histone modifications[J]. Cancer Res,2005,65(24):11367-11374.
    [38] Thiel AT,Blessington P,Zou T,et al. MLL-AF9-induced leukemogenesis requires coexpression of the wild-type Mll allele[J]. Cancer Cell,2010,17(2):148-159.
    [39] Wang QF,Wu G,Mi S,et al. MLL fusion proteins preferentially regulate a subset of wild-type MLL target genes in the leukemic genome[J]. Blood,2011,117(25):6895-6905.
    [40] Dou Y,Milne TA,Ruthenburg AJ,et al. Regulation of MLL1 H3K4 methyltransferase activity by its core components[J]. Nat Struct Mol Biol,2006,13(8):713-719.
    [41] Patel A,Dharmarajan V,Vought VE,et al. On the mechanism of multiple lysine methylation by the human mixed lineage leukemia protein-1(MLL1) core complex[J]. J Biol Chem,2009,284(36):24242-24256.
    [42] Karatas H,Townsend EC,Cao F,et al. High-affinity,small-molecule peptidomimetic inhibitors of MLL1/WDR5 protein-protein interaction[J]. J Am Chem Soc,2013,135(2):669-682.
    [43] Grebien F,Vedadi M,Getlik M,et al. Pharmacological targeting of the WDR5-MLL interaction in C/EBPα n-terminal leukemia[J]. Nat Chem Biol,2015,11(8):571-578.
    [44] Odho Z,Southall SM,Wilson JR. Characterization of a novel WDR5-binding site that recruits RbBP5 through a conserved motif to enhance methylation of histone H3 lysine 4 by mixed lineage leukemia protein-1[J]. J Biol Chem,2010,285(43):32967-32976.
    [45] Gregory GD,Vakoc CR,Rozovskaia T,et al. Mammalian ASH1L is a histone methyltransferase that occupies the transcribed region of active genes[J]. Mol Cell Biol,2007,27(24):8466-8479.
    [46] Chen Z,Yan CT,Dou Y,et al. The role of a newly identified SET domain-containing protein,SETD3,in oncogenesis[J]. Haematologica,2013,98(5):739-743.
    [47] Wang F,Jeon KO,Salovich JM,et al. Discovery of potent 2-aryl-6,7-dihydro-5 h-pyrrolo[1,2-a]imidazoles as WDR5-win-site inhibitors using fragment-based methods and structure-based design[J]. J Med Chem,2018,61(13):5623-5642.
    [48] Getlik M,Smil D,Zepeda-Vel??zquez C,et al. Structure-based optimization of a small molecule antagonist of the interaction between WD repeat-containing protein 5(WDR5) and mixed-lineage leukemia 1(MLL1)[J]. J Med Chem,2016,59(6):2478-2496.
    [49] Zhang P,Lee H,Brunzelle JS,et al. The plasticity of WDR5 peptide-binding cleft enables the binding of the SET1 family of histone methyltransferases[J]. Nucleic Acids Res,2012,40(9):4237-4246.
    [50] Patel A,Vought VE,Dharmarajan V,et al. A conserved arginine-containing motif crucial for the assembly and enzymatic activity of the mixed lineage leukemia protein-1 core complex[J]. J Biol Chem,2008,283(47):32162-32175.
    [51] Karatas H,Townsend EC,Bernard D,et al. Analysis of the binding of mixed lineage leukemia 1(MLL1) and histone 3 peptides to WD repeat domain 5(WDR5) for the design of inhibitors of the MLL1-WDR5 interaction[J]. J Med Chem,2010,53(14):5179-5185.
    [52] Cao F,Townsend EC,Karatas H,et al. Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia[J]. Mol Cell,2014,53(2):247-261.
    [53] Karatas H,Li Y,Liu L,et al. Discovery of a highly potent,cell-permeable macrocyclic peptidomimetic(MM-589) targeting the WD repeat domain 5 protein(WDR5)-mixed lineage leukemia(MLL) protein-protein interaction[J]. J. Med. Chem.,2017,60(12):4818-4839.
    [54] Senisterra G,Wu H,Allali-Hassani A,et al. Small-molecule inhibition of MLL activity by disruption of its interaction with WDR5[J]. Biochem J,2013,449(1):151-159.
    [55] Bolshan Y,Getlik M,Kuznetsova E,et al. Synthesis,optimization,and evaluation of novel small molecules as antagonists of WDR5-MLL interaction[J]. ACS Med Chem Lett,2013,4(3):353-357.
    [56] Li DD,Chen WL,Xu XL,et al. Structure-based design and synthesis of small molecular inhibitors disturbing the interaction of MLL1-WDR5[J]. Eur J Med Chem,2016,118:1-8.
    [57] Chen WL,Chen X,Li DD,et al. Discovery of a potent MLL1 and WDR5 protein-protein interaction inhibitor with in vivo antitumor activity[J]. Eur J Med Chem,2021,223:113677.
    [58] Chen WL,Chen X,Li DD,et al. Discovery of DDO-2213 as a potent and orally bioavailable inhibitor of the WDR5-mixed lineage leukemia 1 protein-protein interaction for the treatment of MLL fusion leukemia[J]. J Med Chem,2021,64(12):8221-8245.
    [59] Rima AA,Methvin I,Babu J,et al. Inhibitor of WDR5 protein-protein binding:
    WO2017147700A1[P]. 2017-09-08
    [60] Rima AA,Methvin I,Babu J,et al. Inhibitor of WDR5 protein-protein binding:
    WO2019046944A1[P]. 2019-03-04
    [61] Aho ER,Wang J,Gogliotti RD,et al. Displacement of WDR5 from chromatin by a WIN site inhibitor with picomolar affinity[J]. Cell Rep,2019,26(11):2916-2928.e13.
    [62] Tian JH,Teuscher KB,Aho ER,et al. Discovery and structure-based optimization of potent and selective WD repeat domain 5(WDR5) inhibitors containing a dihydroisoquinolinone bicyclic core[J]. J Med Chem,2020,63(2):656-675.
    [63] Albert L,Xu J,Wan RW,et al. Controlled inhibition of methyltransferases using photoswitchable peptidomimetics:towards an epigenetic regulation of leukemia[J]. Chem Sci,2017,8(6):4612-4618.
    [64] Chen WL,Li DD,Wang ZH,et al. Design,synthesis,and initial evaluation of affinity-based small molecular probe for detection of WDR5[J]. Bioorg Chem,2018,76:380-385.
    [65] Jian J,Dongxu L,Jing L,et al.
    Wd40 repeat domain protein 5(WDR5) degradation/destruction compound and method of use:
    WO2019246570A1[P]. 2019-12-26
    [66] Avdic V,Zhang P,Lanouette S,et al. Structural and biochemical insights into MLL1 core complex assembly[J]. Structure,2011,19(1):101-108.
计量
  • 文章访问数:  723
  • HTML全文浏览量:  39
  • PDF下载量:  869
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-05-23
  • 修回日期:  2022-03-08
  • 刊出日期:  2022-04-24

目录

    /

    返回文章
    返回
    x 关闭 永久关闭